2024
Pericytes recruited by CCL28 promote vascular normalization after anti-angiogenesis therapy through RA/RXRA/ANGPT1 pathway in lung adenocarcinoma
Chen Y, Zhang Z, Pan F, Li P, Yao W, Chen Y, Xiong L, Wang T, Li Y, Huang G. Pericytes recruited by CCL28 promote vascular normalization after anti-angiogenesis therapy through RA/RXRA/ANGPT1 pathway in lung adenocarcinoma. Journal Of Experimental & Clinical Cancer Research 2024, 43: 210. PMID: 39075504, PMCID: PMC11285179, DOI: 10.1186/s13046-024-03135-3.Peer-Reviewed Original ResearchConceptsAnti-angiogenesis therapyAnti-angiogenesis treatmentVascular normalizationTumor microenvironmentMagnetic-activated cell sortingAnti-angiogenesisTumor tissuesTumor vascular normalizationEfficacy of chemotherapyHuman lung adenocarcinoma cell line A549Expression of CCL28Lung adenocarcinoma cell line A549Adenocarcinoma cell line A549Adenocarcinoma tumor tissuesStabilization of endothelial cellsClinical biopsy samplesRetinoic acidLung adenocarcinoma tumor tissuesCCL28 proteinMurine tumor tissuesCombination therapyTargeted therapyMultiplex immunohistochemistryState of ischemiaPericyte coverage
2020
Integration of Antiangiogenic Therapy with Cisplatin and Gemcitabine Chemotherapy in Patients with Nasopharyngeal Carcinoma
Chong W, Lim C, Sinha A, Tan C, Chan G, Huang Y, Kumarakulasinghe N, Sundar R, Jeyasekharan A, Loh W, Tay J, Yadav K, Wang L, Wong A, Kong L, Soo R, Lau J, Soon Y, Goh R, Ho F, Chong S, Lee S, Loh K, Tai B, Lim Y, Goh B. Integration of Antiangiogenic Therapy with Cisplatin and Gemcitabine Chemotherapy in Patients with Nasopharyngeal Carcinoma. Clinical Cancer Research 2020, 26: 5320-5328. PMID: 32816944, DOI: 10.1158/1078-0432.ccr-20-1727.Peer-Reviewed Original ResearchConceptsLocally advanced nasopharyngeal carcinomaAdvanced nasopharyngeal carcinomaNasopharyngeal carcinomaConcurrent chemoradiationGemcitabine chemotherapyArm CIncreased immune cell infiltrationComplete metabolic responsePosttreatment tumor biopsiesAnti-VEGF therapyArm A patientsRelapse-free survivalMetastatic nasopharyngeal carcinomaImmune cell infiltrationImmune cell traffickingVEGF axisTumor responseInduction cisplatinAntiangiogenic therapyTumor biopsiesTumor perfusionA patientsFDG-PETPericyte coverageStandard treatment
2013
Differential changes in tissue biomarkers after bevacizumab (BEV) alone in a neoadjuvant study of BEV and chemotherapy in ER+ breast cancer (BC) versus triple-negative breast cancer (TNBC) patients (pts).
Boucher Y, Martin J, Tolaney S, Ancukiewicz M, Seano G, Goel S, Yeh E, Meyer J, Isakoff S, Duda D, Winer E, Krop I, Jain R. Differential changes in tissue biomarkers after bevacizumab (BEV) alone in a neoadjuvant study of BEV and chemotherapy in ER+ breast cancer (BC) versus triple-negative breast cancer (TNBC) patients (pts). Journal Of Clinical Oncology 2013, 31: 1065-1065. DOI: 10.1200/jco.2013.31.15_suppl.1065.Peer-Reviewed Original ResearchMean microvascular densityBreast cancerTissue biomarkersAnti-VEGF antibody bevacizumabTriple-negative breast cancer patientsMP scoresHigher pericyte coveragePhase II studyBreast cancer patientsEffectiveness of chemotherapyActivity of bevacizumabNeoadjuvant bevacizumabNeoadjuvant studiesPrimary endpointII studyPathologic responseBEV treatmentBC subtypesVascular functionAntibody bevacizumabCancer patientsMicrovascular densityPericyte coverageBevacizumabChemotherapyHeparanase promotes lymphangiogenesis and tumor invasion in pancreatic neuroendocrine tumors
Hunter K, Palermo C, Kester J, Simpson K, Li J, Tang L, Klimstra D, Vlodavsky I, Joyce J. Heparanase promotes lymphangiogenesis and tumor invasion in pancreatic neuroendocrine tumors. Oncogene 2013, 33: 1799-1808. PMID: 23644656, DOI: 10.1038/onc.2013.142.Peer-Reviewed Original ResearchMeSH KeywordsAnimalsDisease ProgressionFemaleFlow CytometryGlucuronidaseGTPase-Activating ProteinsHeparan Sulfate ProteoglycansHumansImmunohistochemistryLymphangiogenesisMacrophagesMaleMiceMice, Inbred C57BLMice, TransgenicNeoplasm InvasivenessNeovascularization, PathologicNeuroendocrine TumorsPancreatic NeoplasmsConceptsPancreatic neuroendocrine tumorsRIP1-Tag2PanNET patientsNeuroendocrine tumorsTumor invasionPresence of distant metastasesHuman pancreatic neuroendocrine tumorsHeparanase levelsRIP1-Tag2 modelMouse models of cancerHigh tumor gradeAdvanced tumor stageLymphangiogenesis in vivoSpontaneous mouse modelModels of cancerPromote tumor invasionDistant metastasisTumor gradeTumor stageTumor microenvironmentPotential therapeutic targetPericyte coverageIncreased angiogenesisPanNETsMouse model
2011
Upregulated stromal EGFR and vascular remodeling in mouse xenograft models of angiogenesis inhibitor–resistant human lung adenocarcinoma
Cascone T, Herynk MH, Xu L, Du Z, Kadara H, Nilsson MB, Oborn CJ, Park YY, Erez B, Jacoby JJ, Lee JS, Lin HY, Ciardiello F, Herbst RS, Langley RR, Heymach JV. Upregulated stromal EGFR and vascular remodeling in mouse xenograft models of angiogenesis inhibitor–resistant human lung adenocarcinoma. Journal Of Clinical Investigation 2011, 121: 1313-1328. PMID: 21436589, PMCID: PMC3070607, DOI: 10.1172/jci42405.Peer-Reviewed Original ResearchMeSH KeywordsAdenocarcinomaAngiogenesis InhibitorsAnimalsAntibodies, MonoclonalAntibodies, Monoclonal, HumanizedApoptosisBevacizumabCell Line, TumorDrug Resistance, NeoplasmErbB ReceptorsGene Expression ProfilingHumansLung NeoplasmsMaleMiceMice, NudeNeovascularization, PathologicRNA, MessengerRNA, NeoplasmStromal CellsUp-RegulationVascular Endothelial Growth Factor AVascular Endothelial Growth Factor Receptor-2Xenograft Model Antitumor AssaysConceptsMouse xenograft modelHuman lung adenocarcinomaTumor cellsPrimary resistanceLung adenocarcinomaXenograft modelFGFR pathwayProgression-free survivalVEGF inhibitor bevacizumabEndothelium of tumorsInhibitors of angiogenesisCombination regimensTreatment of cancerVEGF inhibitorsPericyte coverageAntiangiogenic therapyVascular remodelingAngiogenesis inhibitorsTherapeutic efficacyTumor growthStromal pathwaysClinical useEGFRAcquired ResistanceEGFR pathway
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply